While BridgeBio Pharma Inc has overperformed by 1.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BBIO rose by 64.43%, with highs and lows ranging from $45.18 to $21.72, whereas the simple moving average jumped by 43.97% in the last 200 days.
On June 17, 2025, Wolfe Research started tracking BridgeBio Pharma Inc (NASDAQ: BBIO) recommending Outperform. A report published by Redburn Atlantic on March 31, 2025, Initiated its previous ‘Buy’ rating for BBIO. Piper Sandler initiated its ‘Overweight’ rating for BBIO, as published in its report on September 04, 2024. Raymond James’s report from March 21, 2024 suggests a price prediction of $45 for BBIO shares, giving the stock a ‘Outperform’ rating. BMO Capital Markets also rated the stock as ‘Market Perform’.
Analysis of BridgeBio Pharma Inc (BBIO)
Further, the quarter-over-quarter decrease in sales is -44.76%, showing a negative trend in the upcoming months.
One of the most important indicators of BridgeBio Pharma Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 4.54, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and BBIO is recording 2.95M average volume. On a monthly basis, the volatility of the stock is set at 4.13%, whereas on a weekly basis, it is put at 3.87%, with a gain of 12.80% over the past seven days. Furthermore, long-term investors anticipate a median target price of $60.56, showing growth from the present price of $45.12, which can serve as yet another indication of whether BBIO is worth investing in or should be passed over.
How Do You Analyze BridgeBio Pharma Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.35%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 85.70% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BBIO shares are owned by institutional investors to the tune of 85.70% at present.
